RELAPSED/REFRACTORY MULTIPLE MYELOMA
Clinical trials for RELAPSED/REFRACTORY MULTIPLE MYELOMA explained in plain language.
Never miss a new study
Get alerted when new RELAPSED/REFRACTORY MULTIPLE MYELOMA trials appear
Sign up with your email to follow new studies for RELAPSED/REFRACTORY MULTIPLE MYELOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New injection method tested for Hard-to-Treat blood cancer
Disease control OngoingThis study is testing whether giving a cancer drug called isatuximab as a simple injection under the skin works as well as the standard method when combined with other medications for multiple myeloma. It involves 118 adults whose cancer has returned or stopped responding after 1…
Matched conditions: RELAPSED/REFRACTORY MULTIPLE MYELOMA
Phase: PHASE2 • Sponsor: Sanofi • Aim: Disease control
Last updated Mar 27, 2026 12:39 UTC
-
New drug combo tested in fight against Tough-to-Treat blood cancer
Disease control OngoingThis study is testing the safety and best dose of an experimental drug called etentamig when given with other standard cancer drugs to adults with multiple myeloma that has come back or stopped responding to prior treatments. The main goal is to see how well patients tolerate the…
Matched conditions: RELAPSED/REFRACTORY MULTIPLE MYELOMA
Phase: PHASE1 • Sponsor: AbbVie • Aim: Disease control
Last updated Mar 23, 2026 15:18 UTC
-
New combo therapy tested for tough blood cancer
Disease control OngoingThis early-stage study is testing the safety of combining two different types of immunotherapy drugs for people with multiple myeloma that has returned or stopped responding to other treatments. The trial will enroll about 74 participants to find safe dose levels and monitor side…
Matched conditions: RELAPSED/REFRACTORY MULTIPLE MYELOMA
Phase: PHASE1 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Mar 12, 2026 13:51 UTC
-
New drug tested to make Cancer-Killing CAR-T therapy last longer
Disease control OngoingThis study is for people with multiple myeloma that has come back or stopped responding to treatment. It tests if adding a new drug called cevostamab, given as an IV infusion every 3 weeks, after a standard CAR-T cell therapy can help keep the cancer in remission. The main goal i…
Matched conditions: RELAPSED/REFRACTORY MULTIPLE MYELOMA
Phase: PHASE2 • Sponsor: University of Pennsylvania • Aim: Disease control
Last updated Mar 03, 2026 14:07 UTC